Trevena (NASDAQ:TRVN) Given “Buy” Rating at Oppenheimer

Oppenheimer restated their buy rating on shares of Trevena (NASDAQ:TRVN) in a research report sent to investors on Monday, November 13th. The firm currently has a $5.00 price target on the biopharmaceutical company’s stock. Oppenheimer also issued estimates for Trevena’s Q1 2018 earnings at ($0.18) EPS, Q2 2018 earnings at ($0.17) EPS, Q3 2018 earnings at ($0.21) EPS and Q4 2018 earnings at ($0.26) EPS.

TRVN has been the subject of several other reports. Zacks Investment Research lowered shares of Trevena from a buy rating to a hold rating in a report on Friday, August 25th. Needham & Company LLC lowered their price objective on shares of Trevena from $9.00 to $7.00 and set a buy rating for the company in a report on Wednesday, November 8th. HC Wainwright restated a buy rating and issued a $5.00 price objective on shares of Trevena in a report on Wednesday, November 8th. Barclays lowered shares of Trevena from an overweight rating to an equal weight rating and lowered their price objective for the stock from $15.00 to $2.50 in a report on Monday, October 16th. Finally, Cowen restated a buy rating and issued a $10.00 price objective on shares of Trevena in a report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. Trevena presently has a consensus rating of Buy and a consensus price target of $8.09.

Trevena (TRVN) traded down $0.01 during trading on Monday, hitting $1.65. 559,904 shares of the stock were exchanged, compared to its average volume of 755,129. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 0.38. Trevena has a one year low of $1.35 and a one year high of $8.00.

Trevena (NASDAQ:TRVN) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.06. During the same quarter in the previous year, the business earned ($0.57) EPS. sell-side analysts predict that Trevena will post -1.25 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in TRVN. Dimensional Fund Advisors LP increased its stake in shares of Trevena by 528.5% during the second quarter. Dimensional Fund Advisors LP now owns 711,615 shares of the biopharmaceutical company’s stock valued at $1,637,000 after purchasing an additional 598,383 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Trevena by 15.0% during the second quarter. Vanguard Group Inc. now owns 1,822,103 shares of the biopharmaceutical company’s stock valued at $4,191,000 after purchasing an additional 238,089 shares in the last quarter. Northern Trust Corp increased its stake in shares of Trevena by 15.8% during the second quarter. Northern Trust Corp now owns 572,662 shares of the biopharmaceutical company’s stock valued at $1,318,000 after purchasing an additional 77,934 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Trevena by 40.4% during the first quarter. Bank of New York Mellon Corp now owns 231,553 shares of the biopharmaceutical company’s stock valued at $851,000 after purchasing an additional 66,577 shares in the last quarter. Finally, Northpointe Capital LLC increased its stake in shares of Trevena by 5.0% during the third quarter. Northpointe Capital LLC now owns 1,283,025 shares of the biopharmaceutical company’s stock valued at $3,272,000 after purchasing an additional 61,546 shares in the last quarter. 56.27% of the stock is owned by institutional investors and hedge funds.

WARNING: “Trevena (NASDAQ:TRVN) Given “Buy” Rating at Oppenheimer” was reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/trevena-inc-trvn-rating-reiterated-by-oppenheimer-holdings-inc/1781628.html.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.